Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies

References

• Gelfand JM. Psoriasis, type 2 diabetes mellitus, and obesity: weighing the evidence. JAMA Dermatol. 2016;152(7):753–754.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2(12):e54.
   PubMed Web of Science ®Google Scholar
• Kumar S, Han J, Li T, et al. Obesity, waist circumference, weight change and the risk of psoriasis in US women. J Euro Acad Dermatol Venereol. 2013;27(10):1293–1298.
   PubMed Web of Science ®Google Scholar
• Bardazzi F, Balestri R, Baldi E, et al. Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy. Dermatol Ther. 2010;23(1):S14–S19.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Del Giglio M, Di Francesco V, et al. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr. 2008;88(5):1242–1247.
   PubMed Web of Science ®Google Scholar
• Chang G, Wang J, Song J, et al. Efficacy and safety of pioglitazone for treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. J Dermatol Treat. 2020;31(7):680–687.
   PubMed Web of Science ®Google Scholar
• Mittal R, Malhotra S, Pandhi P, et al. Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial. Arch Dermatol. 2009;145(4):387–393.
   PubMedGoogle Scholar
• Buysschaert M, Preumont V, Oriot PR, et al. One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice. Diabetes & Metabolism. 2010;36(5):381–388.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153–165.
   PubMed Web of Science ®Google Scholar
• Hogan AE, Tobin AM, Ahern T, et al. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia. 2011;54(11):2745–2754.
   PubMed Web of Science ®Google Scholar
• Ahern T, Tobin AM, Corrigan M, et al. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. J Eur Acad Dermatol Venereol. 2013;27(11):1440–1443.
   PubMed Web of Science ®Google Scholar
• Buysschaert M, Baeck M, Preumont V, et al. Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal γδ T-cell number: a prospective case-series study. Br J Dermatol. 2014;171(1):155–161.
   PubMed Web of Science ®Google Scholar
• Faurschou A, Gyldenløve M, Rohde U, et al. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients-a randomized placebo-controlled trial. J Eur Acad Dermatol Venereol. 2015;29(3):555–559.
   PubMed Web of Science ®Google Scholar
• Xu X, Lin L, Chen P, et al. Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study. Diabetes Res Clin Pract. 2019;150:167–173.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–341.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of WHO consultation; 1999.
   Google Scholar
• Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(1):84–91.
   PubMed Web of Science ®Google Scholar
• Wu CY, Shieh JJ, Shen JL, et al. Association between antidiabetic drugs and psoriasis risk in diabetic patients: results from a nationwide nested case-control study in Taiwan. J Am Acad Dermatol. 2015;72(1):123–130.
   PubMed Web of Science ®Google Scholar
• Faurschou A, Knop FK, Thyssen JP, et al. Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide. Acta Diabetol. 2014;51(1):147–150.
   PubMed Web of Science ®Google Scholar
• Chaudhuri A, Ghanim H, Vora M, et al. Exenatide exerts a potent antiinflammatory effect. J Clin Endocrinol Metabol. 2012;97(1):198–207.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Rosen CF. Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology. Diabetologia. 2011;54(11):2741–2744.
   PubMed Web of Science ®Google Scholar
• Wang XC, Gusdon AM, Liu H, et al. Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation. World J Gastroenterol. 2014;20(40):14821–14830.
   PubMed Web of Science ®Google Scholar
• Faurschou A, Zachariae C, Skov L, et al. Gastric bypass surgery: improving psoriasis through a GLP-1-dependent mechanism?. Med Hypotheses. 2011;77(6):1098–1101.
   PubMed Web of Science ®Google Scholar
• Hattori Y, Jojima T, Tomizawa A, et al. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia. 2010;53(10):2256–2263.
   PubMed Web of Science ®Google Scholar
• Kodera R, Shikata K, Kataoka HU, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia. 2011;54(4):965–978.
   PubMed Web of Science ®Google Scholar
• Reid CT, Tobin AM, Ahern T, et al. Liraglutide in combination with acitretin for severe recalcitrant psoriasis. Br J Dermatol. 2013;169(1):230–231.
   PubMed Web of Science ®Google Scholar